首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1783853

癌症抗体药物复合体的全球市场:市场机会，专利，价格，已核准药物销售和临床试验趋势(2031年)

Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031

出版日期: 2025年08月01日 | 出版商:

KuicK Research | 英文 1300 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

癌症抗体药物复合体的全球市场:市场机会，专利，价格，已核准药物销售和临床试验趋势(2031年)报告结果及亮点

全球癌症抗体-药物偶联物市场机会：到2031年将超过700亿美元
全球及各地区市场规模洞察（年度及季度）：2020年至2025年上半年
全球癌症抗体-药物偶联物市场预测：2026年至2031年
已核准癌症抗体-药物偶联物数量：超过20种抗体-药物偶联物
已核准癌症抗体-药物偶联物的收入洞察： 2020-2025
已核准的癌症抗体-药物偶联物的专利、剂量和价格分析
临床试验中的癌症抗体-药物偶联物：超过800种药物
公司、国家、适应症和阶段划分的癌症抗体-药物偶联物临床试验洞察

对癌症抗体-药物偶联物的需求及本报告的意义

化疗和放疗等传统治疗方法通常毒性大，且缺乏对正常组织的特异性，导致患者治疗选择有限，有时甚至病情严重。因此，对有效且强效的癌症标靶疗法的需求从未如此强烈。从这个意义上讲，癌症抗体药物偶联物 (ADC) 代表了癌症治疗的新前沿，它将单株抗体的选择性与化疗药物的疗效相结合，选择性地杀死癌细胞，同时最大限度地减少对正常组织的损害。全球已有 20 多种抗体-药物偶联物获批，其治疗成功正在彻底改变癌症治疗。

本报告分析了不断扩张的癌症抗体-药物偶联物市场及其在现代肿瘤学中日益重要的作用。报告中还记录了最新的科学进展，监测了临床研发管线趋势，并重点介绍了未来的商业和临床前景，为投资者在这个高风险、高回报的治疗领域提供关键见解。

已核准癌症抗体-药物偶联物的市场机会、销售、定价和剂量洞察

本报告详细概述了20种已核准癌症抗体-药物偶联物在2020年至2025年上半年的定价、建议剂量和销售数据。报告包含全球和区域洞察，以及季度销售业绩分析。报告概述了全球范围内癌症抗体-药物偶联物市场在此期间的总市值，并重点介绍了各个药物对整体市场的贡献。

报告中包含的临床试验洞察

临床试验透过提供抗体-药物偶联物在各种癌症（包括实体癌和血液癌）中的治疗价值洞察，为抗体-药物偶联物的开发提供支持。目前，超过800种癌症抗体-药物偶联物正在临床试验中或已获批，用于评估其在各种癌症适应症中的安全性和有效性，或扩大可治疗的患者群体。例如，阿斯特捷利康和第一三共的TROPION试验系列目前正在评估达泊单抗（dapotamab deruxtecan）在其核准用途之外的各种实体瘤中的应用。 Genmab的RAINFOL试验也正在研究利那巴布（linatabat cestane）在各种实体瘤中的潜力。这些试验对于展示抗体-药物偶联物如何满足大量未满足的医疗需求至关重要。

本报告详细概述了主要癌症抗体-药物偶联物的临床试验，以及抗体-药物偶联物正在测试的适应症、试验申办方、地区背景和试验阶段的数据，旨在帮助利益相关者准确了解当前的开发状态。这些见解对于需要随时了解产品线发展动能和治疗潜力的商业决策者和学术研究人员来说，是一份宝贵的备忘录。

技术平台、合作与协议

开发用于癌症治疗的抗体-药物偶联物需要能够促进将细胞毒性有效载荷靶向递送至癌细胞的技术平台。例如，第一三共的 DXd 平台透过提高稳定性和控制有效载荷释放，推动了 Enhertu 和 Datroway 等抗体-药物偶联物的成功。

策略伙伴关係、收购对象和授权协议也同样重要，它们可以加快开发进度，增加获得新标靶的机会，并促进全球市场准入。这些协议不仅推动了癌症抗体-药物偶联物的创新，也确保了在竞争日益激烈的肿瘤学领域中获得更高的临床疗效和商业成功。

参与癌症抗体药物偶联物研发的主要公司

目前，一些知名製药公司正处于癌症抗体-药物偶联物研发的前沿。例如，辉瑞公司收购了抗体药物偶联物技术领域的领导者Siegen，利用其先进的平台和专业知识，增强了其癌症治疗产品组合。阿斯特捷利康公司也正在加强其癌症抗体-药物偶联物产品线，推出针对多种癌症（包括卵巢癌和乳癌）的候选化合物。像美雅珂这样的新兴生物技术公司，凭藉其前景光明的抗体-药物偶联物MRG003，也正在利用新技术和给药机制来提高疗效并减少副作用，从而引起轰动。

本报告全面分析了推动癌症抗体-药物偶联物创新的关键公司，涵盖传统製药公司、新兴生物技术公司以及新兴技术提供者。报告重点介绍了每家公司的策略重点、产品线开发以及在推动癌症标靶疗法未来发展方面所发挥的作用。

本报告重点介绍了癌症抗体-药物偶联物领域的未来发展方向。

在持续的技术改进、新型有效载荷和改进的连接体系统的推动下，癌症抗体-药物偶联物的未来前景光明。随着新型抗体-药物偶联物（例如用于治疗非小细胞肺癌的Emrelis和用于治疗HER2阳性乳癌的曲妥珠单抗-瑞泽替康）的持续获批，其在肿瘤学领域的潜力日益增长。除了已核准的疗法外，下一代抗体-药物偶联物（例如双特异性和免疫增强型抗体-药物偶联物）也有望彻底改变癌症治疗。这些疗法有望解决肿瘤异质性问题并改善预后。

本报告透过分析科学和监管趋势以及治疗进展，探讨了癌症抗体-药物偶联物行业的未来发展方向，并提供了未来展望。报告强调，需要製定以生物标记为导向的策略、个人化给药和转化试验设计，以最大限度地发挥抗体-药物偶联物在实体癌症和血液癌中的临床潜力。

Global Cancer Antibody Drug Conjugates Market Opportunity: > USD 70 Billion By 2031
Global & Regional Market Size Insight (Yearly & Quarterly): 2020 Till H1'2025
Global Cancer Antibody Drug Conjugates Market Forecast: 2026 Till 2031
Number Of Approved Cancer Antibody Drug Conjugates: > 20 Antibody Drug Conjugates
Approved Cancer Antibody Drug Conjugates Sales Insight : 2020 Till 2025
Approved Cancer Antibody Drug Conjugates Patent, Dosage & Price Analysis
Cancer Antibody Drug Conjugates In Clinical Trials: > 800 Drugs
Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

Need For Cancer Antibody Drug Conjugates & Why This Report?

Traditional treatments such as chemotherapy and radiation are frequently associated with high toxicity and fail to provide the specificity that would allow for sparing of normal tissue, so that patients are left with few and sometimes severe treatment options. Consequently, the demand for effective powerful and targeted cancer therapies has never been greater. In this sense, Cancer Antibody Drug Conjugates (ADCs) represent a new frontier in cancer therapy, marrying the selectivity of monoclonal antibodies with the potency of chemotherapy drugs to selectively kill cancer cells while reducing harm to normal tissue. With over 20 antibody drug conjugates approved globally, their therapeutic success is revolutionizing cancer treatment.

This report provides an analysis of the expanding cancer antibody drug conjugates market and its increasingly prominent role in modern oncology. It also records the most recent scientific advances, monitors developments through clinical pipelines, and identifies future commercial and clinical prospects, thus providing key insight for investors to navigate this high-risk, high-reward therapeutic area.

Market Opportunity, Approved Cancer Antibody Drug Conjugates Sales, Pricing, & Dosing Insight

This report provides a detailed overview of pricing, recommended dosing, and sales data for the 20 approved cancer antibody drug conjugates from 2020 to the first half of 2025. It includes both global and regional insights, along with a quarterly breakdown of sales performance. At the global level, the report outlines the total market value of the cancer antibody drug conjugates market over this period and highlights how each individual drug contributes to overall market figures.

Clinical Trials Insight Included In Report

Clinical trials are at the backbone of antibody drug conjugates development, offering insights into their utility in the treatment of a number of cancers, such as solid tumors and blood cancers. Currently, more than 800 cancer antibody drug conjugates both under investigation and approved, are being tested in clinical trials, aimed at evaluating their safety and efficacy in different cancer indications or broadening their treatable patient population. For instance, AstraZeneca and Daiichi Sankyo's TROPION trial series is currently assessing Datopotamab deruxtecan in a variety of solid tumors outside its approved uses. Genmab's RAINFOL trials are also examining the potential of Rinatabart Sesutecan in various solid tumors. These trials are critical in demonstrating how antibody drug conjugates can address high, unmet medical needs

The report contains an in-depth overview of key cancer antibody drug conjugates clinical trials, along with data on indications being tested by antibody drug conjugates, the trial sponsors, geographic regions and trial phases, providing stakeholders with an accurate picture of the development landscape at present. These observations are a valuable reminder for both commercial decision-makers and academic researchers who need to stay informed of pipeline momentum and therapeutic potential.

Technology Platforms, Collaborations & Agreements

Technology platforms are crucial to the development of antibody drug conjugates for cancer treatment, facilitating targeted delivery of cytotoxic payload to cancer cells. To illustrate this, Daiichi Sankyo's DXd platform has driven the success of antibody drug conjugates such as Enhertu and Datroway, with improved stability and controlled payload release.

Equally important are strategic partnerships, candidate acquisitions and licensing deals, that expedite development timelines, increase access to new targets, and fuel global market reach. These agreements are necessary not only to promote cancer antibody drug conjugates innovation but also to guarantee greater clinical impact and commercial success in an increasingly competitive oncology landscape.

Key Companies Involved in R&D of Cancer Antibody Drug Conjugates

Several prominent drug makers are now active at the forefront of cancer antibody drug conjugates research and development. For instance, Pfizer has enhanced its cancer treatment portfolio by acquiring Seagen, a leader in antibody drug conjugates technology, gaining access to its advanced platform and expertise in the field. AstraZeneca has also strengthened its cancer antibody drug conjugates pipeline, with candidates aiming at a range of cancers, such as ovarian and breast cancers. Emerging biotech firms like Miracogen, with its promising antibody drug conjugates MRG003, are also making waves, centering on new technologies and delivery mechanisms to improve efficacy and reduce side effects.

This report presents a comprehensive analysis of the companies leading cancer antibody drug conjugates innovation, ranging from the traditional pharmaceutical powerhouses to the new biotech upstarts, as well as the occasional technology providers. It identifies each company's strategic emphasis, pipeline development, and role in driving the future of targeted cancer treatment.

Report Highlighting Future Direction of Cancer Antibody Drug Conjugates Segment

The future of cancer antibody drug conjugates is promising, with ongoing technology improvement, new payloads, and improved linker systems. As new antibody drug conjugates continue receiving approval, like Emrelis for non-small cell lung cancer and Trastuzumab rezetecan for HER2-positive breast cancer, their potential in oncology are increasing. Besides those therapies already approved, next-generation antibody drug conjugates, including bispecific antibody drug conjugates and immune-enhancing antibody drug conjugates, are also anticipated to revolutionize cancer therapy. These treatments hold the promise of addressing tumor heterogeneity and enhancing outcome.

Providing a vision of the future, this report examines the future direction of the cancer antibody drug conjugates industry, with analysis of scientific trends, regulatory trends, and therapeutic advances. It highlights the need for biomarker-driven strategies, individualized dosing, and translational trial design in order to realize the maximum clinical potential of antibody drug conjugates in both solid tumors and hematological cancers.

1. RESEARCH METHODOLOGY

2. Introduction To Antibody Drug Conjugates

2.1 Overview
2.2 Mechanism of Antibody Drug Conjugates

3. Antibody Drug Conjugates As Cancer Targeted Therapy

3.1 Applications of Antibody Drug Conjugates in Cancer
3.2 Advantages of Antibody Drug Conjugates
3.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

4. Generations of Antibody Drug Conjugates

4.1 Antibody Drug Conjugates - Evolution
4.2 Next Generation Antibody Drug Conjugates Prospects

5. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

6. Global Cancer Antibody Drug Conjugates Market Outlook

6.1 Current Market Scenario
6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

7.1 US
7.2 China
7.3 Europe
7.4 South Korea
7.5 Australia
7.6 UK
7.7 Canada
7.8 Japan
7.9 India
7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

8.1 Lung Cancer
8.2 Breast cancer
8.3 Leukemia
8.4 Ovarian Cancer
8.5 Gastrointestinal Cancers
8.6 Lymphoma
8.7 Urothelial Carcinoma
8.8 Cervical Cancer
8.9 Head & Neck Cancer
8.10 Brain Cancer
8.11 Prostate cancer
8.12 Pancreatic Cancer
8.13 Skin cancer
8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

This Chapter Gives Comprehensive Insight On Patent, Dosage & Price Analysis For 20 Approved Cancer Antibody Drug Conjugates. We Have Mentioned Few Drug Conjugates Names For Reference, Detailed Insight Included In Sample & Report

10.1 Mylotarg
- 10.1.1 Overview, Availability & Patent Insight
- 10.1.2 Pricing & Dosage Insight
10.2 Adcetris
- 10.2.1 Overview, Availability & Patent Insight
- 10.2.2 Pricing & Dosage Insight
10.3 Kadcyla
- 10.3.1 Overview, Availability & Patent Insight
- 10.3.2 Pricing & Dosage Insight
10.4 Besponsa
- 10.4.1 Overview & Availability Insight
- 10.4.2 Pricing & Dosage Insight
10.5 Lumoxiti (Market Withdrawal In 2023)
- 10.5.1 Overview, Availability & Patent Insight
- 10.5.2 Pricing & Dosage Insight
10.6 Polivy
- 10.6.1 Overview, Availability & Patent Insight
- 10.6.2 Pricing & Dosage Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights 2020 - 2025

11.1 Adcetris
11.2 Padcev
11.3 Tivdak
11.4 Polivy
11.5 Kadcyla
11.6 Besponsa
11.7 Enhertu
11.8 Trodelvy
11.9 Zynlonta
11.10 Elahere
11.11 Blenrep
11.12 Datroway

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

12.1 Research
12.2 Preclinical
12.3 Phase I
12.4 Phase I/II
12.5 Phase II
12.6 Phase II/III
12.7 Phase III
12.8 Preregistration
12.9 Registration

13. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

15.1 Key Market Growth Drivers
15.2 Challenges For Market Growth

16. Competitive Landscape

16.1 ADC Therapeutics
16.2 Affinity Biopharma
16.3 AstraZeneca
16.4 Biocytogen
16.5 Biokin
16.6 Bristol Myers Squibb
16.7 Daiichi Sankyo
16.8 Duality Biologics
16.9 Eli Lilly
16.10 Immunogen
16.11 Innovent Biologics
16.12 LigaChem Biosciences
16.13 Merck
16.14 Pfizer
16.15 Synaffix

简介目录图表

List of Figures

Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
Figure 3-1: Advantages of Antibody Drug Conjugates
Figure 4-1: Antibody-Drug Conjugates - Approval by Generation
Figure 4-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 6-2: Global -Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), H1'2025
Figure 6-3: Global - Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), 2024
Figure 6-4: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2024
Figure 6-5: Global - Cancer Antibody Drug Conjugate Market (US$ Million), Q1-Q4'2024
Figure 6-6: Global - Cancer Antibody Drug Conjugate Market by Drug (US$ Million), 2023
Figure 6-7: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2023
Figure 6-8: Global - Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2025 - 2031
Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), August'2025
Figure 8-1: REFRaME-L1 Phase 2 (NCT06555263) Study - Initiation & Completion Year
Figure 8-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation & Completion Year
Figure 8-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation & Completion Year
Figure 8-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation & Completion Year
Figure 8-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation & Completion Year
Figure 8-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation & Completion Year
Figure 8-7: D926QC00001 Phase 3 (NCT06112379) Study - Initiation & Completion Year
Figure 8-8: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation & Completion Year
Figure 8-9: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation & Completion Year
Figure 8-10: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation & Completion Year
Figure 8-11: CA235-0001 Phase 1 (NCT06419634) Study - Initiation & Completion Year
Figure 8-12: VNC-943-101 Phase 1 (NCT06034275) Study - Initiation & Completion Year
Figure 8-13: RAINFOL-02 Phase 3 (NCT06619236) Study - Initiation & Completion Year
Figure 8-14: RAINFOL-01 Phase 1/2 (NCT05579366) Study - Initiation & Completion Year
Figure 8-15: DS6000-109 Phase 2/3 (NCT06161025) Study - Initiation & Completion Year
Figure 8-16: FONTANA Phase 1/2 (NCT05797168) Study - Initiation & Completion Year
Figure 8-17: LOXO-FRA-24001 Phase 1 (NCT06400472) Study - Initiation & Completion Year
Figure 8-18: M24-427 Phase 1 (NCT06084481) Study - Initiation & Completion Year
Figure 8-19: CUSP06-1001 Phase 1 (NCT06234423) Study - Initiation & Completion Year
Figure 8-20: TROPION-PanTumor03 Phase 2 (NCT05489211) Study - Initiation & Completion Year
Figure 8-21: IKS014-01 Phase 1 (NCT05872295) Study - Initiation & Completion Year
Figure 8-22: D9800C00001 Phase 2 (NCT06219941) Study - Initiation & Completion Year
Figure 8-23: PROCEADE-PanTumor Phase 1/2 (NCT06710132) Study - Initiation & Completion Year
Figure 8-24: CIBI343A101 Phase 1 (NCT05458219) Study - Initiation & Completion Year
Figure 8-25: CTMX-2051-101 Phase 2 (NCT06265688) Study - Initiation & Completion Year
Figure 8-26: M21-404 Phase 1 (NCT05029882) Study - Initiation & Completion Year
Figure 8-27: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
Figure 8-28: ADRX-0405-001 Phase 1 (NCT06710379) Study - Initiation & Completion Year
Figure 8-29: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation & Completion Year
Figure 8-30: RG1122400 Phase 2 (NCT05453396) Study - Initiation & Completion Year
Figure 8-31: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
Figure 8-32: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
Figure 8-33: waveLINE-003 Phase 2/3 (NCT05139017) Study - Initiation & Completion Year
Figure 8-34: waveLINE-010 Phase 3 (NCT06717347) Study - Initiation & Completion Year
Figure 8-35: waveLINE-007 Phase 2 (NCT05406401) Study - Initiation & Completion Year
Figure 8-36: waveLINE-006 Phase 2 (NCT05458297) Study - Initiation & Completion Year
Figure 8-37: SUNMO Phase 3 (NCT05171647) Study - Initiation & Completion Year
Figure 8-38: NCI-2023-00999 Phase 2 (NCT05775471) Study - Initiation & Completion Year
Figure 8-39: RG1122399 Phase 2 (NCT05581589) Study - Initiation & Completion Year
Figure 8-40: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation & Completion Year
Figure 8-41: 9MW2821-2023-CP301 Phase 3 (NCT06196736) Study - Initiation & Completion Year
Figure 8-42: IDE397-001 Phase 1/2 (NCT04794699) Study - Initiation & Completion Year
Figure 8-43: ADCE-T02-01 Phase 1 (NCT06597721) Study - Initiation & Completion Year
Figure 8-44: 2000023639 Phase 2 (NCT05838521) Study - Initiation & Completion Year
Figure 8-45: DESTINY-PanTumor02 Phase 2 (NCT04482309) Study - Initiation & Completion Year
Figure 8-46: 9MW2821-2021-CP102 Phase 1/2 (NCT05216965) Study - Initiation & Completion Year
Figure 8-47: ADRX-0706-001 Phase 1 (NCT06036121) Study - Initiation & Completion Year
Figure 8-48: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
Figure 8-49: SGNDV-005 Phase 2 (NCT06003231) Study - Initiation & Completion Year
Figure 8-50: EV-202 Phase 2 (NCT04225117) Study - Initiation & Completion Year
Figure 8-51: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
Figure 8-52: SGNPDL1V-001 Phase 1 (NCT05208762) Study - Initiation & Completion Year
Figure 8-53: DB-1311-O-1001 Phase 1/2 (NCT05914116) Study - Initiation & Completion Year
Figure 8-54: IRB-43179 Phase 1/2 (NCT03510208) Study - Initiation & Completion Year
Figure 8-55: MEDOPP575 Phase 2 (NCT05865990) Study - Initiation & Completion Year
Figure 8-56: UW18043 Phase 2 (NCT03725761) Study - Initiation & Completion Year
Figure 8-57: ARTEMIS-003 Phase 2 (NCT06001255) Study - Initiation & Completion Year
Figure 8-58: NCI-2021-08857 Phase 1b/2 (NCT05011188) Study - Initiation & Completion Year
Figure 8-59: IDeate-Prostate01 Phase 3 (NCT06925737) Study - Initiation & Completion Year
Figure 8-60: IDeate-PanTumor01 Phase 1/2 (NCT04145622) Study - Initiation & Completion Year
Figure 8-61: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
Figure 8-62: TORL2307ADC-001 Phase 1 (NCT05156866) Study - Initiation & Completion Year
Figure 8-63: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
Figure 8-64: XNW27011-I/II-01 Phase 1/2 (NCT06792435) Study - Initiation & Completion Year
Figure 8-65: BA3021-001 Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
Figure 8-66: CP-MGC018-02 Phase 1 (NCT05293496) Study - Initiation & Completion Year
Figure 8-67: AMT-253-02 Phase 1/2 (NCT06209580) Study - Initiation & Completion Year
Figure 8-68: SGN35-033 Phase 2 (NCT04609566) Study - Initiation & Completion Year
Figure 8-69: BrUOG 413 Phase 2 (NCT05480384) Study - Initiation & Completion Year
Figure 8-70: SYSA1501-010 Phase 1/2 (NCT06577376) Study - Initiation & Completion Year
Figure 8-71: 202401158MIFD Phase 2 (NCT06329869) Study - Initiation & Completion Year
Figure 8-72: HS-20093-203 Phase 2 (NCT06112704) Study - Initiation & Completion Year
Figure 8-73: IDeate-Esophageal01 Phase 2 (NCT06644781) Study - Initiation & Completion Year
Figure 8-74: BL-B01D1-103 Phase 1 (NCT05262491) Study - Initiation & Completion Year
Figure 8-75: IPH4502-101 Phase 1 (NCT06781983) Study - Initiation & Completion Year
Figure 8-76: 9MW2821-2021-CP102 Phase 1 (NCT05216965) Study - Initiation & Completion Year
Figure 9-1: Proprietary ADC Technology - Seagen
Figure 9-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
Figure 9-3: TRAAC - Tallac Therapeutics
Figure 9-4: ATAC - Heidelberg Pharma
Figure 9-5: Tub-tag(R) & P5 - Tubulis
Figure 10-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
Figure 10-2: Mylotarg - Approval Year by Region
Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), July'2025
Figure 10-4: Adcetris - Approval Year by Region
Figure 10-5: US - Adcetris FDA Approval Year by Indication
Figure 10-6: Japan - Adcetris PMDA Approval Year by Indication
Figure 10-7: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 10-8: Adcetris - Patent Expiration by Region
Figure 10-9: Adcetris - Cost of 50 mg Supply in US (US$), July'2025
Figure 10-10: US - Kadcyla FDA Approval Year by Indication
Figure 10-11: Kadcyla - Approval Year by Region
Figure 10-12: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 10-13: Kadcyla - Cost of Supply in US & Europe (US$), July'2025
Figure 10-14: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
Figure 10-15: Besponsa - Approval Year by Region
Figure 10-16: Besponsa - Cost of 0.9 mg Supply in US & 1 mg Supply in Europe, July'2025
Figure 10-17: Lumoxiti - Orphan Designation Years
Figure 10-18: Lumoxiti - Patent Expiry Years
Figure 10-19: Lumoxiti - Cost of 1 mg Supply in US (US$), July'2025
Figure 10-20: Lumoxiti - Cost of 1 mg Supply in US & Europe (US$), July'2025
Figure 10-21: Polivy - Approval Year by Region
Figure 10-22: Polivy - Orphan Drug Designation Approval Year by Region
Figure 10-23: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 10-24: Polivy - Cost of Supply in US & Europe (US$), July'2025
Figure 10-25: Padcev - Approval Year by Region
Figure 10-26: US - Padcev FDA Approval & Patent Expiration Year
Figure 10-27: Padcev - Cost of Supply In US & Europe (US$), July'2025
Figure 10-28: Enhertu - Approval Year by Region
Figure 10-29: US - Polivy FDA Approval Year by Indication
Figure 10-30: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
Figure 10-31: Enhertu - Cost of 100 mg Supply In US & Europe (US$), July'2025
Figure 10-32: US - Trodelvy FDA Approval by Indication
Figure 10-33: Trodelvy - Approval Year by Region
Figure 10-34: Trodelvy - Patent Expiration by Region
Figure 10-35: Trodelvy - Cost of Supply In US & Europe (US$), July'2025
Figure 10-36: Blenrep - FDA & EMA Orphan Drug Designations
Figure 10-37: Blenrep - FDA & EMA Approval
Figure 10-38: Zynlonta - FDA & EMA Approval Years
Figure 10-39: Zynlonta - FDA & EMA Orphan Drug Designation Years
Figure 10-40: Zynlonta - Cost of 10 mg Supply In US & Europe (US$), July'2025
Figure 10-41: Tivdak - Cost of 40 mg Supply Europe (US$), July'2025
Figure 10-42: Ujvira - Cost of 100 mg & 160 mg Supply in India (US$), July'2025
Figure 10-43: Akalux - Sakigake Designation & PMDA Approval Year
Figure 10-44: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
Figure 10-45: Datroway - Cost of 100 mg Supply In US & Europe (US$), July'2025
Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2025
Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2025
Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2025
Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2025
Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-12: Polivy - Global Sales By Region (%), H1'2025
Figure 11-13: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-14: Polivy - Global Sales By Region (US$ Million), 2024
Figure 11-15: Polivy - Global Sales By Region (%), 2024
Figure 11-16: Polivy - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-17: Polivy - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-18: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-19: Polivy - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-20: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-21: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-22: Polivy - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-24: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-25: Polivy - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-26: Polivy - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-27: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-28: Kadcyla - Global Sales Values (US$ Million), 2020-2025
Figure 11-29: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-30: Kadcyla - Global Sales By Region (%), H1'2025
Figure 11-31: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-32: Kadcyla - Global Sales By Region (US$ Million), 2024
Figure 11-33: Kadcyla - Global Sales By Region (%), 2024
Figure 11-34: Kadcyla - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-35: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-36: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-37: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-38: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1'2025
Figure 11-39: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-40: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-41: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-42: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-43: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-44: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-45: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
Figure 11-46: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 11-47: Besponsa - Global Sales by Region (US$ Million), 2023
Figure 11-48: Besponsa - Quarterly Sales by Region (%), Q1-Q4'2024
Figure 11-49: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-50: Besponsa - US Annual Sales (US$ Million), 2020-2023
Figure 11-51: Besponsa - Europe Quarterly Sales (US$ Million), 2022
Figure 11-52: Besponsa - ROW Quarterly Sales (US$ Million), 2022
Figure 11-53: Enhertu - Global Annual Sales (US$ Million), 2020-2025
Figure 11-54: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
Figure 11-55: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-56: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
Figure 11-57: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-58: Trodelvy - Annual Sales By Region (US$ Million), 2025
Figure 11-59: Trodelvy - Annual Sales By Region (%), 2025
Figure 11-60: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-61: Trodelvy - Annual Sales By Region (US$ Million), 2024
Figure 11-62: Trodelvy - Annual Sales By Region (%), 2024
Figure 11-63: Trodelvy - US Annual Sales (US$ Million), 2020-2025
Figure 11-64: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-65: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-66: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
Figure 11-67: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-68: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-69: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
Figure 11-70: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-71: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-72: Zynlonta - Global Annual Sales (US$ Million), 2021-2025
Figure 11-73: Zynlonta - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-74: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-75: Elahere - Global Annual Sales (US$ Million), 2022-2025
Figure 11-76: Elahere - Global Quarterly Sales (US$ Million), Q1-Q2'2025
Figure 11-77: Elahere - Global Quarterly Sales by Region (US$ Million), H2'2025
Figure 11-78: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-79: Blenrep - Global Annual Sales (US$ Million), 2020-2025
Figure 11-80: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4'2024
Figure 11-81: Datroway - Global Annual Sales (US$ Million), 2025
Figure 12-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2031
Figure 14-1: Antibody Drug Conjugate Combinations in Studies
Figure 14-2: Approved Antibody Drug Conjugate Combinations

List of Tables

Table 4-1: First Generation Antibody Drug Conjugates - Examples
Table 4-2: Second Generation Antibody Drug Conjugates - Examples
Table 4-3: Third Generation Antibody Drug Conjugates - Examples
Table 4-4: Fourth Generation Antibody Drug Conjugates - Examples
Table 5-1: Approved Antibody Drug Conjugates, July'2025
Table 6-1: Cancer Antibody Drug Conjugates - Recent Collaborations
Table 6-2: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
Table 6-3: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
Table 6-4: Cancer Antibody Drug Conjugates - Recent IND Clearances
Table 7-1: US - Approved Cancer Antibody Drug Conjugates, May'2025
Table 7-2: China - Approved Antibody Drug Conjugates, July'2025
Table 7-3: EU - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-4: Australia - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-5: UK - Approved Antibody Drug Conjugates, July'2025
Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, July'2025
Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, July'2025
Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates, July'2025
Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates, July'2025
Table 8-3: Leukemia - Approved Antibody Drug Conjugates, July'2025
Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
Table 8-9: Head & Neck Cancer - Approved Antibody Drug Conjugates
Table 10-1: Adcetris - Recommended Dosage
Table 10-2: Datroway - Premedication and Concomitant Medications
Table 10-3: Datroway - Recommended Dosage Reductions for Adverse Reactions
Table 10-4: Emrelis: Recommended Dose Reductions
Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials

02-2729-4219

+886-2-2729-4219

License/价格

癌症抗体药物复合体的全球市场:市场机会，专利，价格，已核准药物销售和临床试验趋势(2031年)

Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031

目录

第1章调查手法

第2章抗体药物复合体的简介

第3章癌症标靶治疗的抗体药物复合体

第4章抗体药物复合体的世代

第5章就品牌名，公司名，各适应症里来看市售核准抗体药物复合体

第6章全球癌症抗体药物复合体市场展望

第7章全球癌症抗体药物复合体的调查与市场趋势(各地区)

第8章全球癌症抗体药物复合体市场趋势与各适应症的开发

第9章各企业癌症抗体药物复合体开发平台

第10章已核准癌症抗体药物偶联物 - 专利、剂量与定价分析

第11章已通过核准癌症抗体药物复合体:2020年～2025年的销售趋势

第12章企业，国家，适应症，各相的世界癌症抗体药物复合体临床试验的洞察

第13章市售被做的癌症抗体药物复合体的临床试验:企业，国家，适应症，各相

第14章癌症抗体药物复合体的联合治疗

第15章全球癌症抗体药物复合体市场概要

第16章竞争情形